Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 May 2022

Zhang Chenzhi, Li Dandan, Xiao Binyi, Zhou Chi, Jiang Wu, Tang Jinghua, Li Yuan, Zhang Rongxin, Han Kai, Hou Zhenlin, Zhang Linjie, Sui Qiaoqi, Liao Leen, Pan Zhizhong, Zhang Xiaoshi, Ding Peirong

Abstract excerpt

β2-microglobulin (B2M) and Janus kinases 1 and 2 (JAK1/2) mutations have been suggested as genetic mechanisms of immune evasion for anti-programmed cell death protein 1 (PD-1) therapy. Whether B2M and JAK1/2 lose-of-function mutation can cause primary resistance to anti-PD-1 therapy in colorectal carcinoma (CRC) patients remains controversial. Here, we sought to compare the efficacy of anti-PD-1 therapy in DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta 2-Microglobulin
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Janus Kinase 1

Share to Janus Kinase 2

Share to Microsatellite Instability

Share to Neoplastic Syndromes, Hereditary

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 35343934
DOI: 10.1097/CJI.0000000000000417
PMCID: PMC8986629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.PMID 35343934Read ↗

Majority of B2M -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-HighSemantic proximity Read ↗

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer LandscapeSemantic proximity Read ↗

Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studySemantic proximity Read ↗

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.Semantic proximity Read ↗

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.Semantic proximity Read ↗

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacySemantic proximity Read ↗

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read ↗

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.Semantic proximity Read ↗

Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancersSemantic proximity Read ↗

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsSemantic proximity Read ↗

Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of CareSemantic proximity Read ↗

Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advancesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.